Microbiome Sequencing Market Overview:
Microbiome sequencing is the analysis of microbial groups located in and on the human body. The objective of human microbiome research is to comprehend the function of microbes in health and disease. Conventionally, examining samples from human skin, stool, or blood was dependent on time and labour-intensive microbiology procedures of growing and isolating individual organisms followed by phenotypic or genotypic analysis. However, the arrival of next-generation sequencing (NGS) has enabled numerous high-profile collaborative projects, which have published an extensive range of data on the human microbiome utilizing NGS as a foundational tool. Main factors fuelling the market development are the rising utilization of microbiomes in genomics, proteomics, and metabolomics and mechanical headways in cutting edge sequencing. Then again, the absence of adequate regulations, government directions, and moral and legitimate issues identified with NGS are the main considerations limiting the development of microbiome sequencing services market.
Microbiome Sequencing Services Market Size Growth Rate and Analysis
Microbiome sequencing services market size was around USD 722.93 Million in 2018. It is expected to grow at a CAGR of 21.5% to reach USD 1914.6 Million by 2023.
Detailed Segmentation of Microbiome Sequencing Services Industry:
Microbiome Sequencing Services -Technology
Microbiome Sequencing Services - Application
Microbiome Sequencing Services -Research type
Microbiome Sequencing Services - Laboratory type
Microbiome Sequencing Services - End user
Geographical Classification of Microbiome Sequencing Services Industry:
Competitor Analysis and Key Players Mentioned in this Market are:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Technology
5.1.1 Introduction
5.1.2 sequencing by synthesis
5.1.3 sequencing by ligation
5.1.4 pyrosequencing
5.1.5 sanger sequencing
5.1.6 Other technologies
5.1.7 Y-o-Y Growth Analysis, By Technology
5.1.8 Market Attractiveness Analysis, By Technology
5.1.9 Market Share Analysis, By Technology
5.2 Application
5.2.1 Introduction
5.2.2 shotgun sequencing
5.2.3 targeted gene sequencing
5.2.4 RNA sequencing
5.2.5 whole genome sequencing
5.2.6 Other applications
5.2.7 Y-o-Y Growth Analysis, By Application
5.2.8 Market Attractiveness Analysis, By Application
5.2.9 Market Share Analysis, By Application
5.3 Research type
5.3.1 Introduction
5.3.2 Internal research
5.3.3 Outsourced researchDrug
5.3.4 Y-o-Y Growth Analysis, By research type
5.3.5 Market Attractiveness Analysis, By research type
5.3.6 Market Share Analysis, By research type
5.4 Laboratory type
5.4.1 Introduction
5.4.2 Wet lab
5.4.3 Dry lab
5.4.4 Y-o-Y Growth Analysis, By Laboratory type
5.4.5 Market Attractiveness Analysis, By Laboratory type
5.4.6 Market Share Analysis, By Laboratory type
5.5 End user
5.5.1 Introduction
5.5.2 Pharmaceutical
5.5.3 Biotechnology
5.5.4 Y-o-Y Growth Analysis, By End user
5.5.5 Market Attractiveness Analysis, By End user
5.5.6 Market Share Analysis, By End user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Technology
6.1.3.3 By Application
6.1.3.4 By Research type
6.1.3.5 By laboratory type
6.1.3.6 By End user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Technology
6.1.4.3 By Application
6.1.4.4 By Research type
6.1.4.5 By laboratory type
6.1.4.6 By End user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Technology
6.1.5.3 By Application
6.1.5.4 By Research type
6.1.5.5 By laboratory type
6.1.5.6 By End user
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Metabiomics Corp
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Microbiome Therapeutics LLC
8.3 Microbiome Insights Inc.
8.4 Rancho Biosciences
8.5 Zymo Research Corp
8.6 Molzym GmbH & Co.
8.7 Celgene Corporation
8.8 Ubiome Inc.
8.9 Diversigen Inc.
8.10 Merieux Nutrisciences Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
